Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedApr 03, 2026
DataAggregated Company Financials
Companies147
  • 7D3.1%
  • 3M-2.3%
  • 1Y1.4%
  • YTD-2.3%

Over the last 7 days, the Healthcare industry has risen 3.1%, driven by gains from Swedish Orphan Biovitrum of 4.6%. In the same time, Diamyd Medical was down 90%. The industry has been flat over the past 12 months despite the gain this week. Looking forward, earnings are forecast to grow by 24% annually.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 03 Apr 2026SEK 570.5bSEK 228.8b-SEK 2,931,785,094.4130.9x-194.6x2.5x
Sun, 01 Mar 2026SEK 567.3bSEK 229.0b-SEK 2,338,686,563.1433.4x-242.6x2.5x
Tue, 27 Jan 2026SEK 602.0bSEK 257.7bSEK 4.9b38.8x123.9x2.3x
Thu, 25 Dec 2025SEK 583.9bSEK 230.5bSEK 3.6b43.6x160.1x2.5x
Sat, 22 Nov 2025SEK 583.3bSEK 230.8bSEK 3.3b44.2x178.8x2.5x
Mon, 20 Oct 2025SEK 601.1bSEK 227.1bSEK 6.7b42.6x89.8x2.6x
Wed, 17 Sep 2025SEK 607.6bSEK 227.1bSEK 6.6b44.7x92.1x2.7x
Fri, 15 Aug 2025SEK 609.0bSEK 226.8bSEK 6.6b46.4x92.3x2.7x
Sun, 13 Jul 2025SEK 630.8bSEK 226.6bSEK 6.0b44.8x104.7x2.8x
Tue, 10 Jun 2025SEK 632.9bSEK 226.4bSEK 5.8b43.6x108.8x2.8x
Thu, 08 May 2025SEK 590.0bSEK 224.0bSEK 4.8b37.8x121.7x2.6x
Sat, 05 Apr 2025SEK 537.6bSEK 221.5bSEK 5.4b32.5x99.5x2.4x
Mon, 03 Mar 2025SEK 588.0bSEK 206.6bSEK 4.3b35.8x135.6x2.8x
Wed, 29 Jan 2025SEK 584.0bSEK 202.6b-SEK 2,675,858,022.8940.8x-218.3x2.9x
Fri, 27 Dec 2024SEK 577.8bSEK 202.8b-SEK 2,503,902,169.1638.4x-230.7x2.8x
Sun, 24 Nov 2024SEK 506.5bSEK 199.8b-SEK 2,653,445,983.7436.2x-190.9x2.5x
Tue, 22 Oct 2024SEK 596.7bSEK 198.9b-SEK 3,206,372,252.8841.7x-186.1x3x
Thu, 19 Sep 2024SEK 616.7bSEK 200.1b-SEK 2,795,442,136.9440.9x-220.6x3.1x
Sat, 17 Aug 2024SEK 599.0bSEK 199.9b-SEK 2,540,884,670.9841x-235.8x3x
Mon, 15 Jul 2024SEK 585.4bSEK 196.2b-SEK 3,104,678,694.3238.3x-188.5x3x
Wed, 12 Jun 2024SEK 557.0bSEK 195.5b-SEK 3,081,091,991.8535.6x-180.8x2.8x
Fri, 10 May 2024SEK 545.0bSEK 196.8b-SEK 2,715,029,099.5135.5x-200.7x2.8x
Sun, 07 Apr 2024SEK 523.8bSEK 192.8b-SEK 3,173,203,050.4345.6x-165.1x2.7x
Tue, 05 Mar 2024SEK 508.0bSEK 192.2b-SEK 3,659,835,641.3244.4x-138.8x2.6x
Thu, 01 Feb 2024SEK 656.1bSEK 191.7b-SEK 795,100,988.0048.4x-825.1x3.4x
Sat, 30 Dec 2023SEK 542.0bSEK 191.2b-SEK 963,322,468.0048.2x-562.6x2.8x
Mon, 27 Nov 2023SEK 501.3bSEK 190.1b-SEK 1,201,055,298.0050.2x-417.4x2.6x
Wed, 25 Oct 2023SEK 424.7bSEK 186.5b-SEK 1,835,419,558.0034.7x-231.4x2.3x
Fri, 22 Sep 2023SEK 459.7bSEK 185.7b-SEK 2,030,087,413.0036.5x-226.4x2.5x
Sun, 20 Aug 2023SEK 457.5bSEK 185.0b-SEK 1,091,744,910.0037.5x-419.1x2.5x
Tue, 18 Jul 2023SEK 462.9bSEK 179.9b-SEK 1,545,729,692.0044.7x-299.5x2.6x
Thu, 15 Jun 2023SEK 523.3bSEK 178.9b-SEK 772,164,165.0045.9x-677.6x2.9x
Sat, 13 May 2023SEK 518.0bSEK 177.0b-SEK 880,129,490.0042.2x-588.5x2.9x
Mon, 10 Apr 2023SEK 504.0bSEK 172.7b-SEK 1,424,880,805.0035.7x-353.7x2.9x
Price to Earnings Ratio

-353.7x


Total Market Cap: SEK 504.0bTotal Earnings: -SEK 1,424,880,805.00Total Revenue: SEK 172.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -163.8x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swedish Healthcare industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 2.7x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 9.8% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market2.57%
Healthcare3.06%
Healthtech4.92%
Pharma4.01%
Biotech3.16%
Life Sciences2.91%
Medical Equipment2.87%
Healthcare Services1.51%
Industry PE
  • Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio of 116x.
    • Analysts are expecting annual earnings growth of 20.2%, which is higher than its past year's earnings growth of 1.5% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 35% over the next 5 years.
  • This is better than its past earnings growth rate of 14% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings grow by 19% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SOBI Swedish Orphan BiovitrumSEK 400.804.6%
+SEK 6.2b		42.7%PE289.8x
SECT B SectraSEK 235.605.2%
+SEK 2.2b		-6.1%PE84.5x
BONEX Bonesupport HoldingSEK 214.2013.8%
+SEK 1.7b		-32.3%PE100.6x
CAMX CamurusSEK 483.605.8%
+SEK 1.6b		-14.4%PE39.3x
IMP A SDB ImplanticaSEK 45.9511.5%
+SEK 1.3b		64.1%PS577x

Latest News

EKTA B
SEK 54.45
Elekta
7D
-2.0%
1Y
8.5%

EKTA B: Future Outlook Balances Mixed Ratings With Product Adoption Progress

Analysts lifted their fair value estimate for Elekta to SEK 58.27 from SEK 56.77, reflecting a higher assumed future P/E and recent Street research, where one firm raised its price target to SEK 60 while another turned more cautious on the shares. Analyst Commentary Bullish Takeaways Bullish analysts see the higher SEK 60 price target as better aligned with the updated fair value estimate, which now builds in a higher assumed P/E multiple.
CRNO B
SEK 6.49
Cereno Scientific
7D
-2.6%
1Y
8.5%
BONEX
SEK 214.20
Bonesupport Holding
7D
13.8%
1Y
-32.3%
SOBI
SEK 400.80
Swedish Orphan Biovitrum
7D
4.6%
1Y
42.7%
ARJO B
SEK 25.32
Arjo
7D
-1.0%
1Y
-27.0%
DMYD B
SEK 1.42
Diamyd Medical
7D
-90.2%
1Y
-83.2%
CAMX
SEK 483.60
Camurus
7D
5.8%
1Y
-14.4%

CAMX: FDA Review Of Resubmitted NDA Will Drive Future Upside

Analysts have trimmed their 12 month price target for Camurus from SEK 660 to SEK 610, citing updated assumptions that include revised revenue growth, profit margin and future P/E expectations. What's in the News Camurus issued earnings guidance for 2026, with expected revenues of SEK 2.6b to SEK 2.9b and an operating result of SEK 0.9b to SEK 1.2b, framed against internal 2025 expectations (Key Developments).
GETI B
SEK 191.20
Getinge
7D
2.2%
1Y
-6.9%

Getinge AB (publ) Just Missed EPS By 11%: Here's What Analysts Think Will Happen Next

Mar 29
Getinge AB (publ) Just Missed EPS By 11%: Here's What Analysts Think Will Happen Next
BIOA B
SEK 327.40
BioArctic
7D
3.2%
1Y
86.6%
MVIR
SEK 2.35
Medivir
7D
-3.9%
1Y
83.9%

Rare Disease And Liver Cancer Pipeline Will Transform Long Term Prospects

Catalysts About Medivir Medivir is a biotech company focused on developing first in class therapies in oncology and rare bone diseases, alongside partnered programs in animal health. What are the underlying business or industry changes driving this perspective?
VIMIAN
SEK 28.68
Vimian Group
7D
6.6%
1Y
-30.0%
SECT B
SEK 235.60
Sectra
7D
5.2%
1Y
-6.1%

SECT B: Cloud Deals And Rating Upgrades Will Shape Balanced Return Profile

Sectra's analyst price target has been revised from SEK 220 to about SEK 228. Analysts have issued refreshed Buy ratings and higher targets in the SEK 210 to SEK 250 range that reflect updated views on growth, profitability and future P/E assumptions.
FLERIE
SEK 29.70
Flerie
7D
-17.0%
1Y
-29.8%
ORT B
SEK 7.98
Ortoma
7D
-17.2%
1Y
-11.1%
IMP A SDB
SEK 45.95
Implantica
7D
11.5%
1Y
64.1%
CINPHA
SEK 16.30
Cinclus Pharma Holding
7D
-5.7%
1Y
43.0%